Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Thrue CA"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Løvendorf MB; Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark., Holm A; Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark.; Department of Clinical Experimental Research, Rigshopitalet, Glostrup, Denmark., Petri A; Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark., Thrue CA; Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark., Uchida S; Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark., Venø MT; Omiics ApS, Aarhus, Denmark., Kauppinen S; Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark.
Publikováno v:
Nucleic acid therapeutics [Nucleic Acid Ther] 2023 Jan; Vol. 33 (1), pp. 45-57. Date of Electronic Publication: 2022 Nov 23.
Autor:
Tsukamoto S; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Løvendorf MB; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University Campus Copenhagen, Copenhagen, Denmark., Park J; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Salem KZ; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Reagan MR; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Maine Medical Center Research Institute, Scarborough, ME, USA., Manier S; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Zavidij O; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Rahmat M; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Huynh D; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Takagi S; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Kawano Y; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Kokubun K; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Thrue CA; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University Campus Copenhagen, Copenhagen, Denmark.; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Nagano K; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Harvard Medical School, Boston, MA, USA., Petri A; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University Campus Copenhagen, Copenhagen, Denmark.; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Roccaro AM; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; ASST Spedali Civili di Brescia, Clinical Research Development and Phase I Unit, Brescia, BS, Italy., Capelletti M; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Baron R; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Harvard Medical School, Boston, MA, USA., Kauppinen S; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University Campus Copenhagen, Copenhagen, Denmark. ska@dcm.aau.dk.; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark. ska@dcm.aau.dk., Ghobrial IM; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Leukemia [Leukemia] 2018 Aug; Vol. 32 (8), pp. 1739-1750. Date of Electronic Publication: 2018 Jun 20.
Autor:
Petri A; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Dybkær K; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Bøgsted M; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Thrue CA; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Hagedorn PH; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Schmitz A; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Bødker JS; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Johnsen HE; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Kauppinen S; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.
Publikováno v:
PloS one [PLoS One] 2015 Sep 22; Vol. 10 (9), pp. e0138236. Date of Electronic Publication: 2015 Sep 22 (Print Publication: 2015).
Autor:
Lyngaa R; Authors' Affiliations: Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark; General Dermatology, Medical University of Graz, Graz, Austria; Departments of Medicine/Dermatology, Pathology, University of Washington; Fred Hutchinson Cancer Research Center, Seattle Cancer Center Care Alliance, Seattle, Washington; and Department of Oncology, University Hospital Herlev, Herlev, Denmark., Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, Thor Straten P, Nghiem P, Becker JC, Hadrup SR
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Apr 01; Vol. 20 (7), pp. 1768-78. Date of Electronic Publication: 2014 Feb 13.
Autor:
Kvistborg P; The Netherlands Cancer Institute; Department of Immunology; Amsterdam, The Netherlands., Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN
Publikováno v:
Oncoimmunology [Oncoimmunology] 2012 Jul 01; Vol. 1 (4), pp. 409-418.
Autor:
Andersen RS; Department of Hematology, Center for Cancer Immune Therapy and Oncology, University Hospital Herlev, Herlev, Denmark., Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR
Publikováno v:
Cancer research [Cancer Res] 2012 Apr 01; Vol. 72 (7), pp. 1642-50. Date of Electronic Publication: 2012 Feb 06.
Autor:
Hansen JB; Research Division, Santaris Pharma A/S, Boege alle 3, Hoersholm 2970 Denmark. bh@santaris.com, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, Rosenbohm C, Wissenbach M, Orum H, Koch T
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2008 Sep; Vol. 7 (9), pp. 2736-45.
Autor:
Hansen JB; Cureon A/S, Copenhagen, Denmark. bh@cureon.com, Westergaard M, Thrue CA, Giwercman B, Oerum H
Publikováno v:
Nucleosides, nucleotides & nucleic acids [Nucleosides Nucleotides Nucleic Acids] 2003 May-Aug; Vol. 22 (5-8), pp. 1607-9.